Clinical Trials Logo

Rickets clinical trials

View clinical trials related to Rickets.

Filter by:

NCT ID: NCT00417612 Completed - Hyperparathyroidism Clinical Trials

Effectiveness of Paricalcitol in Reducing Parathyroid Hormone (PTH) Levels in X-linked Hypophosphatemic Rickets

Start date: January 2007
Phase: Phase 3
Study type: Interventional

The purpose of this study is to determine the effectiveness of paricalcitol, a form of synthetic vitamin D, in lowering parathyroid hormone (PTH) levels and reducing disease symptoms in children and adults with X-linked hypophosphatemic (XLH) rickets.

NCT ID: NCT00204906 Completed - Hypovitaminosis D Clinical Trials

Correction of Vitamin D Inadequacy in Nursing Home Residents

Start date: January 2005
Phase: N/A
Study type: Interventional

Vitamin D inadequacy continues to be neglected in nursing home residents. We hypothesized that part of this neglect is due to absence of data documenting safe and effective ways to replete this inadequacy.

NCT ID: NCT00195936 Completed - Clinical trials for Hypophosphatemic Rickets, X-Linked Dominant

Effect of Cinacalcet on Parathyroid Hormone Secretion in Children and Adolescents With Hypophosphatemic Rickets

Start date: June 2005
Phase: Phase 1
Study type: Interventional

This study will measure the effect of cinacalcet (Sensipar) on parathyroid hormone (PTH) secretion in children and adolescents with hypophosphatemic rickets (XLH). The investigators are seeking evidence that patients with XLH may benefit from treatment with cinacalcet by achieving better control of PTH secretion.

NCT ID: NCT00001242 Completed - Hypocalcemia Clinical Trials

Studies of States With Resistance to Vitamin D and Parathyroid Hormone

Start date: August 12, 1997
Phase:
Study type: Observational

Patients with confirmed or suspected states with resistance to vitamin D or parathyroid hormone (PTH) will be admitted for diagnosis, treatment review with suggestions for modifications to the current or new treatment and for inclusion in other protocols. These states include hypocalcemia, rickets, osteomalacia, pseudohypoparathyroidism. Resistance to a factor is manifested by deficient bioeffect despite high levels of the factor in blood. Patients will be tested with multiple indices of mineral metabolism to establish the diagnosis and examine the spectrum of the underlying disorder. The principal therapies will be combinations of calcium, phosphate, and a vitamin D analog. Selected patients will have localization and surgery to remove a tumor that causes renal wasting of phosphate. Patients will also be considered for entry into other research protocols.